GILEAD SCIENCES, INC. (GILD) Form 8-K — Aug 4, 2026
Gilead Sciences reported second-quarter 2026 total revenues of $7.8 billion, up 10% year over year, with product sales excluding Veklury up 10% to $7.6 billion on strength in HIV (up 12% to $5.7 billion), Trodelvy (up 26%) and Livdelzi. The company swung to a GAAP diluted loss per share of $(8.45) and a non-GAAP loss of $(6.75), driven by a $(9.08) per-share hit from $11.2 billion of acquired IPR&D charges tied to the Arcellx, Tubulis and Ouro Medicines acquisitions plus a $1.75 billion IPR&D impairment on assets previously acquired from Immunomedics.
Key figures
- Revenue
- 7803000000
- Guidance
- FY2026 product sales $30.1B-$30.4B (raised low end from $30.0B); product sales excluding Veklury $29.8B-$30.1B (raised from $29.4B-$29.8B); Veklury ~$300M (cut from ~$600M); GAAP diluted loss per share $(3.75)-$(3.40); non-GAAP diluted loss per share $(0.65)-$(0.30) (improved from $(1.05)-$(0.65))
- Revenue Yoy
- 10%
- Total Assets
- 49362000000
- Cash Position
- 3179000000
- Hiv Sales
- 5693000000
- Q2 Buybacks
- 355000000
- Hiv Sales Yoy
- 12%
- Descovy Sales
- 967000000
- Veklury Sales
- 23000000
- Biktarvy Sales
- 3772000000
- Trodelvy Sales
- 457000000
- Iprd Impairment
- 1750000000
- Descovy Sales Yoy
- 48%
- Q2 Dividends Paid
- 1000000000
- Veklury Sales Yoy
- -81%
- Cell Therapy Sales
- 417000000
- Term Loan Borrowed
- 1100000000
- Trodelvy Sales Yoy
- 26%
- Liver Disease Sales
- 877000000
- Senior Notes Issued
- 3000000000
- Shares Outstanding
- 1241000000
- Product Gross Margin
- 79.3%
- Cell Therapy Sales Yoy
- -14%
- Operating Cash Flow Q2
- 3573000000
- Acquired IPRDExpenses
- 11183000000
- Product Sales Ex Veklury
- 7604000000
- Dividend Per Share Declared
- 0.82
- Non Gaa Product Gross Margin
- 86.9%
- Tubulis Upfront Consideration
- 3150000000
Price after filing
Close on the filing date to close N calendar days later (from $131.28). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.